Skip to main content

Table 4 Incidence of CMV disease and asymptomatic CMV infection in R+ recipients according to era after HTx

From: Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients

Era Prophylaxis CMV disease, n (%) Asymptomatic CMV infection, n (%) No CMV, n (%)
1988–1991 (n = 59) No 11 (19) 8 (13) 40 (68)
1992–1997 (n = 74) Targeteda 11 (15) 17 (23) 46 (62)
1998–2000 (n = 32) Targeteda 10 (31) 6 (19) 16 (50)
Total (n = 165)   32 (19) 31 (19) 102 (62)
  1. aTargeted prophylaxis given with 5 mg/kg of i.v. ganciclovir bid for 10 days in association with the first anti-rejection treatment with ATG and the second anti-rejection treatment with high-dose corticosteroids within the first 4 months post-transplantation